-
公开(公告)号：US20100311820A1
公开(公告)日：2010-12-09
申请号：US12793572
申请日：2010-06-03
CPC分类号： C12N15/115 , C12N2310/113 , C12N2310/16 , C12N2310/315 , C12N2310/321 , C12N2310/351 , C12N2320/50 , C12N2310/3521
摘要： The present invention relates, in general, to a pharmacologic system to modulate the biology of platelets based upon a nucleic acid ligand that can interact with and modulate the activity of platelet glycoprotein GPVI to regulate platelet function. These nucleic acid ligands are also actively reversible using a modulator that inhibits the activity of the nucleic acid ligand to neutralize this pharmacologic effect and thereby restore GPVI function, including collagen binding, platelet adhesion, collagen-induced platelet activation, and collagen-induced platelet aggregation. The invention further relates to compositions comprising the nucleic acid ligand, the ligand and a modulator, methods to generate the nucleic acid ligand and its modulator, as well as methods of using these agents and compositions in medical therapeutic and diagnostic procedures.
摘要翻译： 本发明一般涉及基于可与血小板糖蛋白GPVI相互作用并调节血小板糖蛋白GPVI的活性以调节血小板功能的核酸配体调节血小板生物学的药理学系统。 这些核酸配体也可以使用抑制核酸配体的活性来中和这种药理作用并由此恢复GPVI功能的调节剂，包括胶原结合，血小板粘附，胶原诱导的血小板活化和胶原诱导的血小板聚集 。 本发明还涉及包含核酸配体，配体和调节剂的组合物，产生核酸配体及其调节剂的方法，以及在医学治疗和诊断程序中使用这些试剂和组合物的方法。
-
公开(公告)号：US20120095085A1
公开(公告)日：2012-04-19
申请号：US13274189
申请日：2011-10-14
申请人： JULIANA M. LAYZER , Sanjoy K. Mahanty , Samuel C. Wolff , Catherine C. Redick , Christopher P. Rusconi
发明人： JULIANA M. LAYZER , Sanjoy K. Mahanty , Samuel C. Wolff , Catherine C. Redick , Christopher P. Rusconi
IPC分类号： A61K31/7088 , A61P7/02 , C07H21/04 , C07H21/02 , G01N21/84
CPC分类号： C12N15/115 , C12N15/1138 , C12N2310/16 , C12N2310/322 , C12N2310/3533
摘要： Provided are ligands which bind to and regulate the function of CLEC-2. Nucleic acid CLEC-2 ligands described herein are able to inhibit CLEC-2 mediated platelet aggregation and may also provide use in regulating CLEC-2-mediated processes such as thrombus formation, tumor metastasis, lymphangiogenesis, HIV dissemination, inflammatory response, cytokine production and phagocytosis. Also disclosed herein are modulator molecules which can reverse the activity of the CLEC-2 ligand both in vitro and in vivo and ex vivo.
摘要翻译： 提供了结合和调节CLEC-2功能的配体。 本文所述的核酸CLEC-2配体能够抑制CLEC-2介导的血小板聚集，并且还可用于调节CLEC-2介导的过程，例如血栓形成，肿瘤转移，淋巴管生成，HIV传播，炎症反应，细胞因子产生和 吞噬作用 本文还公开了可以在体外和体内以及体外逆转CLEC-2配体的活性的调节分子。
-
公开(公告)号：US20090163437A1
公开(公告)日：2009-06-25
申请号：US12252994
申请日：2008-10-16
IPC分类号： A61K31/7088
CPC分类号： C12N15/115 , C12N2310/113 , C12N2310/16 , C12N2310/351 , C12N2320/31 , C12N2320/32 , C12N2320/35
摘要： An improved method of administration of an aptamer and modulator system to regulate blood coagulation in a host is provided wherein the aptamer is administered subcutaneously and the modulator is administered either subcutaneously or intravenously. This method for sustained aptamer activity using intermittent subcutaneous injections further allows for titrated modulation of the aptamer activity by administration of the modulator.
摘要翻译： 提供改进的适配体和调节剂系统的调节方法以调节宿主中的血液凝固，其中适体被皮下施用，调节剂以皮下或静脉内施用。 使用间歇皮下注射的持续适体活性的这种方法还允许通过施用调节剂滴定调节适体活性。
-
公开(公告)号：US07531524B2
公开(公告)日：2009-05-12
申请号：US11546190
申请日：2006-10-11
CPC分类号： C12N15/115 , A61K31/711 , A61K47/60 , A61K48/00 , C07H21/02 , C08G65/329 , C08L2203/02 , C12N2310/16 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/531 , C12N2310/3521
摘要： The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.
摘要翻译： 本发明提供改进的核酸配体，其具有增强的稳定性，其抑制凝血和改进的核酸调节剂以提供理想的凝血调节剂。 这些改进的核酸和调节剂特别可用于抑制经历诸如手术或冠状动脉旁路治疗方案的宿主中的凝血。
-
公开(公告)号：US20080125383A1
公开(公告)日：2008-05-29
申请号：US11546190
申请日：2006-10-11
IPC分类号： A61K31/711 , A01N1/02 , A61P7/02 , C07H21/02
CPC分类号： C12N15/115 , A61K31/711 , A61K47/60 , A61K48/00 , C07H21/02 , C08G65/329 , C08L2203/02 , C12N2310/16 , C12N2310/321 , C12N2310/322 , C12N2310/351 , C12N2310/531 , C12N2310/3521
摘要： The invention provides improved nucleic acid ligands with enhanced stability that inhibit coagulation and improved modulators of the nucleic acids to provide ideal modulators of coagulation. These improved nucleic acids and modulators are particularly useful for inhibiting coagulation in a host undergoing a therapeutic regime such as surgery or coronary artery bypass.
摘要翻译： 本发明提供改进的核酸配体，其具有增强的稳定性，其抑制凝血和改进的核酸调节剂以提供理想的凝血调节剂。 这些改进的核酸和调节剂特别可用于抑制经历诸如手术或冠状动脉旁路治疗方案的宿主中的凝血。
-
-
-
-
搜索结果
25 条记录 (耗时 0.027 秒)
